To that end, Lee et al. [96] conducted a randomized phase II clinical trial in chemo-native, EGFR-anaplastic lymphoma kinase (ALK) wild-type, stage IIIB/IV NSCLC patients. This evidence concerns the gene EGFR and non-small cell lung carcinoma.